A gut bacterium from the Japanese tree frog accumulated 3,000-fold inside tumors within 24 hours — then vanished from every healthy organ. One intravenous dose. Complete remission.
A bacterium isolated from the gut of the Japanese tree frog Dryophytes japonicus produced complete tumor remission in a mouse colorectal cancer model after a single intravenous dose. That result comes from a preclinical study evaluating nine bacterial strains from amphibian and reptile intestinal microbiomes — eight of those nine strains showed significant antitumor effects. Ewingella americana stood out most sharply.
The mechanism behind that result is what makes it genuinely strange. The bacterium doesn’t just reach the tumor — it floods it, exploiting conditions that defeat most drugs.
How Ewingella americana Accumulates Inside Tumors While Sparing Healthy Organs
Solid tumors generate a distinctive microenvironment: low oxygen, disrupted vasculature, and elevated acidity. E. americana is a facultative anaerobe, meaning it thrives under low-oxygen conditions that healthy tissue rarely presents.
That biology explains the distribution data. The bacterium’s blood half-life was approximately 1.2 hours, and it was undetectable in circulation by 24 hours. Simultaneously, tumor tissue bacterial counts reached ~3,000-fold while normal organs registered nothing. This is not a designed targeting system — it is a mechanistic fit between the bacterium’s metabolic preferences and the tumor’s unusual chemistry.
The Dual Killing Mechanism: Direct Cytotoxicity Plus Immune Activation
Most cancer therapies work through one route. E. americana appears to work through two simultaneously. The study documented direct tumor cell killing alongside elevated inflammatory cytokines — including TNF-α and IFN-γ — and measurable recruitment of immune effector cells into the tumor.
That immune activation matters beyond the immediate response. Mice resisted a second tumor rechallenge after achieving remission, which points to immune memory rather than a transient cytotoxic effect. Transient inflammatory responses from the bacterium itself normalized within 72 hours, and no chronic toxicity appeared across a 60-day observation period.
What This Finding Is and Is Not
This is preclinical animal research. The 100% complete response rate and 100% survival were observed in a mouse colorectal cancer model. Those numbers have not been tested in humans, and the distance from mouse model to clinical therapy is substantial.
What the study does establish is a reproducible, mechanistically explained antitumor phenomenon — one that appeared in eight of nine bacterial strains evaluated, not just a single anomalous isolate.
The finding sits at an unusual intersection: a common gut bacterium, an amphibian host, and a tumor microenvironment that turns out to be a perfect habitat. The frog didn’t know it was carrying a potential cancer therapy. The biology simply fit.
Frequently Asked Questions
What is Ewingella americana?
Ewingella americana is a gram-negative bacterium isolated from the intestinal microbiome of the Japanese tree frog Dryophytes japonicus, recently studied for antitumor activity in mice.
How does a gut bacterium find a tumor?
E. americana is a facultative anaerobe that preferentially grows in low-oxygen environments — conditions common inside solid tumors but rare in healthy organs.
Has this been tested in humans?
No. All results reported are from a mouse colorectal cancer model. Human clinical testing has not been conducted.
Did one dose really produce complete remission?
In the mouse model, a single intravenous administration produced complete tumor remission with 100% survival in treated animals. This has not been replicated in humans.